Edgewise Therapeutics (EWTX) Projected to Post Quarterly Earnings on Monday

Edgewise Therapeutics (NASDAQ:EWTX) is expected to announce its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Edgewise Therapeutics Price Performance

Shares of EWTX stock opened at $29.31 on Monday. The business’s fifty day moving average price is $26.91 and its 200 day moving average price is $20.67. The firm has a market capitalization of $3.10 billion, a PE ratio of -18.55 and a beta of 0.27. Edgewise Therapeutics has a 1-year low of $10.60 and a 1-year high of $31.29.

Insider Transactions at Edgewise Therapeutics

In other Edgewise Therapeutics news, Director Badreddin Edris sold 115,471 shares of Edgewise Therapeutics stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $29.44, for a total transaction of $3,399,466.24. Following the completion of the transaction, the director owned 19,820 shares in the company, valued at approximately $583,500.80. The trade was a 85.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 23.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of EWTX. Canada Pension Plan Investment Board purchased a new stake in Edgewise Therapeutics in the 2nd quarter valued at approximately $45,000. Jones Financial Companies Lllp acquired a new position in shares of Edgewise Therapeutics in the first quarter worth $47,000. Steward Partners Investment Advisory LLC raised its holdings in shares of Edgewise Therapeutics by 23.9% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock worth $71,000 after acquiring an additional 550 shares during the last quarter. Strs Ohio purchased a new stake in shares of Edgewise Therapeutics in the first quarter valued at $84,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Edgewise Therapeutics by 48.9% during the second quarter. BNP Paribas Financial Markets now owns 8,193 shares of the company’s stock valued at $107,000 after acquiring an additional 2,689 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on EWTX shares. Wall Street Zen raised shares of Edgewise Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, February 15th. Royal Bank Of Canada boosted their price objective on shares of Edgewise Therapeutics from $49.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Wedbush dropped their target price on shares of Edgewise Therapeutics from $35.00 to $32.00 and set an “outperform” rating for the company in a report on Friday, November 7th. JPMorgan Chase & Co. lifted their price target on shares of Edgewise Therapeutics from $33.00 to $34.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Finally, Piper Sandler reissued an “overweight” rating on shares of Edgewise Therapeutics in a research note on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.67.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.